Some Severe COVID-19 Cases Linked to Genetic Mutations or Antibodies that Attack the Body

Newswise — People infected by the novel coronavirus can have symptoms that range from mild to deadly. Now, two new analyses suggest that some life-threatening cases can be traced to weak spots in patients’ immune systems.

At least 3.5 percent of study patients with severe COVID-19, the disease caused by the novel coronavirus, have mutations in genes involved in antiviral defense. And at least 10 percent of patients with severe disease create “auto-antibodies” that attack the immune system, instead of fighting the virus. The results, reported in two papers in the journal Science on September 24, 2020, identify some root causes of life-threatening COVID-19, says study leader Jean-Laurent Casanova, a Howard Hughes Medical Institute Investigator at The Rockefeller University.

Seeing these harmful antibodies in so many patients – 101 out of 987 – was “a stunning observation,” he says. “These two papers provide the first explanation for why COVID-19 can be so severe in some people, while most others infected by the same virus are okay.”

The work has immediate implications for diagnostics and treatment, Casanova says. If someone tests positive for the virus, they should “absolutely” be tested for the auto-antibodies, too, he adds, “with medical follow-up if those tests are positive.” It’s possible that removing such antibodies from the blood could ease symptoms of the disease.

A global effort

Casanova’s team, in collaboration with clinicians around the world, first began enrolling COVID-19 patients in their study in February. At the time, they were seeking young people with severe forms of the disease to investigate whether these patients might have underlying weaknesses in their immune systems that made them especially vulnerable to the virus.

The plan was to scan patients’ genomes – in particular, a set of 13 genes involved in interferon immunity against influenza. In healthy people, interferon molecules act as the body’s security system. They detect invading viruses and bacteria and sound the alarm, which brings other immune defenders to the scene.

Casanova’s team has previously discovered genetic mutations that hinder interferon production and function. People with these mutations are more vulnerable to certain pathogens, including those that cause influenza. Finding similar mutations in people with COVID-19, the team thought, could help doctors identify patients at risk of developing severe forms of the disease. It could also point to new directions for treatment, he says.

In March, Casanova’s team was aiming to enroll 500 patients with severe COVID-19 worldwide in their study. By August, they had more than 1,500, and they now have over 3,000. As the researchers began analyzing patient samples, they started to uncover harmful mutations, in people young and old. The team found that 23 out of 659 patients studied carried errors in genes involved in producing antiviral interferons, the team found.

Without a full complement of these antiviral defenders, COVID-19 patients wouldn’t be able to fend off the virus, the researchers suspected. That thought sparked a new idea. Maybe other patients with severe COVID-19 also lacked interferons – but for a different reason. Maybe some patients’ bodies were harming these molecules themselves. As in autoimmune disorders such as type 1 diabetes and rheumatoid arthritis, some patients might be making antibodies that target the body. “That was the eureka moment for us,” Casanova says.

The team’s analysis of 987 patients with life-threatening COVID-19 revealed just that. At least 101 of the patients had auto-antibodies against an assortment of interferon proteins. “We said, ‘bingo’!” Casanova remembers. These antibodies blocked interferon action and were not present in patients with mild COVID-19 cases, the researchers discovered.

“It’s an unprecedented finding,” says study co-author Isabelle Meyts, a pediatrician at the University Hospitals KU Leuven, in Belgium, who earlier this year helped enroll patients in the study, gather samples, and perform experiments. By testing for the presence of these antibodies, she says, “you can almost predict who will become severely ill.”

The vast majority – 94 percent – of patients with the harmful antibodies were men, the team found. Men are more likely to develop severe forms of COVID-19, and this work offers one explanation for that gender variability, Meyts says.

Casanova’s lab is now looking for the genetic driver behind those auto-antibodies. They could be linked to mutations on the X chromosome, he says. Such mutations might not affect women, because they have a second X chromosome to compensate for any defects in the first. But for men, who carry only a single X, even small genetic errors can be consequential.

Looking ahead

Clinically, the team’s new work could change how doctors and health officials think about vaccination distribution strategies, and even potential treatments. A clinical trial could examine, for instance, whether infected people who have the auto-antibodies benefit from treatment with one of the 17 interferons not neutralized by the auto-antibodies, or with plasmapheresis, a medical procedure that strips the antibodies from patients’ blood. Either method could potentially counteract the effect of these harmful antibodies, Meyts says.

In addition to the current work, Meyts, Casanova, and hundreds of other scientists involved with an international consortium called the COVID Human Genetic Effort are working to understand a second piece of the coronavirus puzzle. Instead of hunting for factors that make patients especially vulnerable to COVID-19, they’re looking for the opposite – genetic factors that might be protective. They’re now recruiting people from the households of patients with severe COVID-19 – people who were exposed to the virus but did not develop the disease. “Our lab is currently running at full speed,” Casanova says.

###

Citations

Paul Bastard et al. “Autoantibodies against type I IFNs in patients with life-threatening COVID-19.” Science. Published online September 24, 2020. doi: 10.1126/science.abd4585

Qian Zhang et al. “Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.” Science. Published online September 24, 2020. doi: 10.1126/science.abd4570

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 3817
Released: 30-Oct-2020 6:35 PM EDT
UCLA Health infectious disease experts tout critical role mask wearing plays in limiting spread of COVID-19
University of California, Los Angeles (UCLA), Health Sciences

With thousands of new cases logged daily and a vaccine to fight COVID-19 still in development, UCLA Health infectious disease experts are encouraging people to continue to wear masks as the best method of protecting against virus transmission.

Released: 30-Oct-2020 5:35 PM EDT
Surgeon General expects COVID-19 vaccine to be available by year’s end
University of California, Los Angeles (UCLA), Health Sciences

In a wide-ranging talk with UCLA Health physicians, Wednesday, Oct. 28, United States Surgeon General Jerome Adams, MD, MPH, addressed the politicization of the pandemic and the means of containing the spread of COVID-19. He also offered hope that a vaccine for the virus will be available by year’s end.

Released: 30-Oct-2020 4:15 PM EDT
Study shows myocarditis linked to COVID-19 not as common as believed
Louisiana State University Health Sciences Center - New Orleans

A study conducted by Richard Vander Heide, MD, PhD, Professor and Director of Pathology Research at LSU Health New Orleans School of Medicine, and Marc Halushka, MD, PhD, Professor of Pathology at Johns Hopkins University School of Medicine, suggests myocarditis caused by COVID-19 may be a relatively rare occurrence.

access_time Embargo lifts in 2 days
Embargo will expire: 3-Nov-2020 11:00 AM EST Released to reporters: 30-Oct-2020 3:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 3-Nov-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: 247373_web.jpg
Released: 30-Oct-2020 2:30 PM EDT
Researcher develops app to reach Black community with COVID-19 information
University of Cincinnati

A University of Cincinnati cardiologist is partnering with researchers in St. Louis and rural Georgia to develop a smartphone app that will deliver COVID-19 information and education that is targeted toward Black communities.

Newswise: 247467_web.jpg
Released: 30-Oct-2020 1:55 PM EDT
SARS-CoV-2 might attack red marrow and block new erythrocytes formation
Far Eastern Federal University

Specialists from the Department of Fundamental Medicine of Far Eastern Federal University (FEFU) with Russian and Japanese colleagues have probed into mechanisms of COVID-19 inside-the-body distribution linked to erythrocytes damaging. According to researchers, the virus might attack red marrow, thus being detrimental not only for erythrocytes in the bloodstream but also for the process of the formation of the new ones.

Released: 30-Oct-2020 12:40 PM EDT
Government of Canada awards $2.5M to McMaster University to support the COVID-19 border study with McMaster HealthLabs
McMaster University

McMaster University has been awarded $2.5 million from the Government of Canada to support the McMaster HealthLabs (MHL) Canadian International COVID-19 Surveillance Border Study at Toronto Pearson International Airport, being run in partnership with Air Canada and the Greater Toronto Airports Authority (GTAA).

Released: 30-Oct-2020 12:00 PM EDT
5 Big Questions on Health Care and COVID-19
University of Virginia Darden School of Business

The coronavirus pandemic has once again thrust the unusual state of American health care into the spotlight. With a presidential election that could have a dramatic impact on the state of health care for millions on 3 November, Professor Vivian Riefberg considers the state of the industry.

Newswise: Infection by Confection: COVID-19 and the Risk of Trick-or-Treating
Released: 30-Oct-2020 11:05 AM EDT
Infection by Confection: COVID-19 and the Risk of Trick-or-Treating
University of California San Diego Health

Researchers determined that COVID-19 transmission risk via Halloween candies is low, even when they are handled by infected people, but handwashing and disinfecting collected sweets reduces risk even further.

Newswise:Video Embedded third-spike-in-covid-19-cases-plus-the-vaccine-trials-live-expert-panel-for-october-29-3pm-edt
VIDEO
Released: 30-Oct-2020 9:40 AM EDT
TRANSCRIPT AND VIDEO AVAILABLE: "Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29
Newswise

"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT


Showing results

110 of 3817

close
1.05531